http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Upper-Limb Rehabilitation Exercises Using Haptic Device System
Yoshiyuki Takahashi,Takafumi Terade,Kaoru Inoue,Yuko Ito,Hokyoo Lee,Takashi Komeda 한국과학기술원 인간친화 복지 로봇 시스템 연구센터 2003 International Journal of Assistive Robotics and Me Vol.4 No.2
We have applied a haptic device to the rehabilitation tool and made efforts to integrate the motion and sensory therapy, in order to avoid boredom that the patients usually feel. This rehabilitation tool system consists of a haptic device, a display, a computer, and software for training. When the user moves the grip, the haptic device provides a virtual force and it can either assists the movement of the arm or work against it. We have carried out a preliminary experiment with young and middle age group and elderly group. It aims to confirm the functionality of this system and to collect the reference data for the evaluation of the upper-limb disability. The results of our experiment show that the system could be used to evaluate the patient"s ability of upper-limb motion.
Cheng, Yang,Wang, Yue,Ito, Daisuke,Kong, Deok-Hoon,Ha, Kwon-Soo,Chen, Jun-Hu,Lu, Feng,Li, Jian,Wang, Bo,Takashima, Eizo,Sattabongkot, Jetsumon,Tsuboi, Takafumi,Han, Eun-Taek American Society for Microbiology 2013 Infection and immunity Vol.81 No.5
<P>Merozoite surface protein 1 of <I>Plasmodium vivax</I> (PvMSP1), a glycosylphosphatidylinositol-anchored protein (GPI-AP), is a malaria vaccine candidate for <I>P. vivax</I>. The paralog of PvMSP1, named <I>P. vivax</I> merozoite surface protein 1 paralog (PvMSP1P; PlasmoDB PVX_099975), was recently identified and predicted as a GPI-AP. The similarities in genetic structural characteristics between PvMSP1 and PvMSP1P (e.g., size of open reading frames, two epidermal growth factor-like domains, and GPI anchor motif in the C terminus) led us to study this protein. In the present study, different regions of the PvMSP1P protein, demarcated based on the processed forms of PvMSP1, were expressed successfully as recombinant proteins [i.e., 83 (A, B, and C), 30, 38, 42, 33, and 19 fragments]. We studied the naturally acquired immune response against each fragment of recombinant PvMSP1P and the potential ability of each fragment to bind erythrocytes. The N-terminal fragment (83A) and two C-terminal fragments (33 and 19) reacted strongly with sera from <I>P. vivax</I>-infected patients, with 50 to 68% sensitivity and 95 to 96% specificity, respectively. Due to colocalization of PvMSP1P with PvMSP1, we supposed that PvMSP1P plays a similar role as PvMSP1 during erythrocyte invasion. An <I>in vitro</I> cytoadherence assay showed that PvMSP1P, especially the 19-kDa C-terminal region, could bind to erythrocytes. We also found that human sera from populations naturally exposed to vivax malaria and antisera obtained by immunization using the recombinant molecule PvMSP1P-19 inhibited <I>in vitro</I> binding of human erythrocytes to PvMSP1P-19. These results provide further evidence that the PvMSP1P might be an essential parasite adhesion molecule in the <I>P. vivax</I> merozoite and is a potential vaccine candidate against <I>P. vivax</I>.</P>
Takeshi Chida,Kazuhito Kawata,Kazuyoshi Ohta,Erika Matsunaga,Jun Ito,Shin Shimoyama,Satoru Yamazaki,Hidenao Noritake,Tetsuro Suzuki,Takafumi Suda,Yoshimasa Kobayashi 거트앤리버 소화기연관학회협의회 2018 Gut and Liver Vol.12 No.2
Background/Aims: Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. Methods: Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV). Results: Total, LDL-, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL- and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels. Conclusions: Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.